{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:32Z","timestamp":1790890472952,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40801-020-00192-w","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T15:40:24Z","timestamp":1593186024000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience"],"prefix":"10.1007","volume":"7","author":[{"given":"Lauren E.","family":"Brownell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan L.","family":"Adamsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"Vanderloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"192_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285\u201392.","journal-title":"Clin Infect Dis"},{"key":"192_CR2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275\u20139.","journal-title":"Pharmacotherapy"},{"key":"192_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","volume":"77","author":"MN Jeffres","year":"2017","unstructured":"Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77:1143\u201354.","journal-title":"Drugs"},{"key":"192_CR4","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180\u201390.","journal-title":"N Engl J Med"},{"key":"192_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"G Ralph Corey","year":"2015","unstructured":"Ralph Corey G, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254\u201362.","journal-title":"Clin Infect Dis"},{"key":"192_CR6","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s40265-015-0478-7","volume":"75","author":"YY Syed","year":"2015","unstructured":"Syed YY, Scott LJ. Oritavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75:1891\u2013902.","journal-title":"Drugs"},{"key":"192_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ofid\/ofx277","volume":"5","author":"R Datta","year":"2018","unstructured":"Datta R, McManus D, Topal J, Juthani-Mehta M. Long-acting lipoglycopeptides for gram-positive bacteremia at the end of life to facilitate hospice care: a report of 3 cases. Open Forum Infect Dis. 2018;5:15\u20137.","journal-title":"Open Forum Infect Dis"},{"key":"192_CR8","doi-asserted-by":"crossref","unstructured":"Johnson JA, Feeney ER, Kubiak DW, Corey GR. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis 2015;2:ofv156.","DOI":"10.1093\/ofid\/ofv156"},{"key":"192_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/phar.2057","volume":"38","author":"LT Schulz","year":"2018","unstructured":"Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38:152\u20139.","journal-title":"Pharmacotherapy"},{"key":"192_CR10","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","volume":"24","author":"BJ Werth","year":"2018","unstructured":"Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24:429.e1\u2013.e5.","journal-title":"Clin Microbiol Infect"},{"key":"192_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"192_CR12","unstructured":"Kaiser Family Foundation Hospital Adjusted Expenses per Inpatient Day. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed 1 Oct 2018."},{"key":"192_CR13","unstructured":"Centers for Medicare and Medicaid Services. Inpatient charge data FY 2015. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Inpatient2015.html. Accessed 11 May 2018."},{"key":"192_CR14","unstructured":"United States Bureau of Labor. Inflation calculator. https:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed 1 Oct 2018."},{"key":"192_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","volume":"6","author":"CL Stewart","year":"2017","unstructured":"Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6:277\u201389.","journal-title":"Infect Dis Ther"},{"key":"192_CR16","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/phar.1957","volume":"37","author":"DJ Delaportas","year":"2017","unstructured":"Delaportas DJ, Estrada SJ, Darmelio M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy. 2017;37:e90\u2013e9292.","journal-title":"Pharmacotherapy"},{"key":"192_CR17","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/jac\/dkq355","volume":"65","author":"J Ho","year":"2010","unstructured":"Ho J, Archuleta S, Sulaiman Z, Fisher D. Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service. J Antimicrob Chemother. 2010;65:2641\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"192_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","volume":"38","author":"TP Lodise","year":"2016","unstructured":"Lodise TP, Fan W, Sulham KA. Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations. Clin Ther. 2016;38:136\u201347.","journal-title":"Clin Ther"},{"key":"192_CR19","doi-asserted-by":"crossref","unstructured":"Jensen IS, Wu E, Fan W, et al. Use of oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: a U.S. payer budget impact analysis. J Manag Care Spec Pharm 2016;22:752\u201364.","DOI":"10.18553\/jmcp.2016.22.6.752"},{"key":"192_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40261-015-0365-8","volume":"36","author":"IS Jensen","year":"2016","unstructured":"Jensen IS, Lodise TP, Fan W, et al. Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: a US hospital budget impact analysis. Clin Drug Invest. 2016;36:157\u201368.","journal-title":"Clin Drug Invest"},{"key":"192_CR21","doi-asserted-by":"crossref","unstructured":"Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376\u201386.","DOI":"10.1111\/j.1742-1241.2008.01958.x"},{"key":"192_CR22","unstructured":"Li H-K et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med.\u00a0380.5 (2019):425\u201336."},{"key":"192_CR23","doi-asserted-by":"crossref","unstructured":"Iversen K et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 380.5 (2019):415\u201324.","DOI":"10.1056\/NEJMoa1808312"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-020-00192-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T23:11:25Z","timestamp":1624662685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-020-00192-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":23,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s40801-020-00192-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"26 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the conduct of this study or the preparation of this manuscript. This manuscript is part of a supplement wholly funded by Melinta Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LTS has received compensation for Speaker\u2019s Bureau activities from Melinta Therapeutics. LB, MA, EKM, JPV, EJE, and ERJ have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was deemed quality assurance\/improvement by the local institutional review board as it posed minimal risk to patients in the study. The study was performed in accordance with the ethical standards of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}